Breaking Down Last Week's Impactful Stock Buybacks: What Investors Need to Know

Bristol Myers authorized a $4 billion stock buyback program last week and these 8 other companies announced similar plans



Sector: Healthcare
Industry: Medical Devices

Sensus Healthcare, Inc. (SRTS), a pioneering medical device firm renowned for its cutting-edge solutions in non-invasive and minimally-invasive treatments for a wide spectrum of medical conditions. In a strategic move, the company's Board of Directors has recently given the green light for a fresh share repurchase initiative. This program empowers Sensus Healthcare to buy back a substantial sum of its own common stock, amounting to an impressive cap of $3.0 million.

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 48 full-time employees. The firm designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy. The superficial radiation therapy is an alternative to surgical basal cell carcinoma treatment and squamous cell carcinoma treatment. The firm''s product, the SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions, such as keloids. The SRT-100 treats primary lesions that would otherwise be difficult or require surgery involving sensitive areas of the head and neck regions, such as the fold in the nose, eyelids, lips, corner of the mouth and the lining of the ear.


Sector: Technology
Industry: Computer Hardware

Nano Dimension Ltd. (Nasdaq: NNDM), a pioneering force in Additively Manufactured Electronics (AME) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (AM) 3D printers, recently unveiled a strategic move that has investors buzzing. The company's board of directors greenlit a substantial share repurchase plan, tagged the "Repurchase Plan," giving Nano Dimension the green light to allocate up to a substantial $227.5 million for the repurchase of its American Depository Shares (ADS).

This bold move underscores Nano Dimension's commitment to enhancing shareholder value and capitalizing on what seems to be a favorable market landscape. The Repurchase Plan provides the company's management with the flexibility to execute repurchases through diverse avenues - from open market transactions to private negotiations - all in compliance with stringent U.S. securities laws and regulations, along with applicable Israeli laws. Crucially, these measures are calibrated to safeguard the company's overall financial stability and ongoing obligations.

Nano Dimension Ltd is an Israel-based additive electronics provider active in the technology sector. With its 3D printing technology for printed electronics, the Company targets the growing demand for electronic devices that require sophisticated features and rely on encapsulated sensors, antennas and printed circuit boards (PCBs). The Company''s PCB Jet printer system is an inkjet deposition tool for printing multi-layer circuit boards at home or office. It uses hardware, software, print-head management and nano-chemistry for Research and Development (R&D), prototyping and custom manufacturing projects. The Company targets a range of industry sectors, such as consumer electronics, medical devices and defense, aerospace, automotive, Internet of Things (IoT) and telecom.


Sector: Technology
Industry: Semiconductors

Rambus Inc. (RMBS) has taken a significant step by partnering with Royal Bank of Canada to embark on an accelerated share repurchase program, aiming to buy back around $100 million of its own common stock. This move comes as a testament to Rambus' confidence in its sustained growth trajectory, as stated by Luc Seraphin, the company's President and CEO. With a robust balance sheet and robust cash flow, Rambus is committed to delivering substantial value to its shareholders.

Under this accelerated share repurchase program, Rambus will make an upfront payment of $100 million to Royal Bank of Canada, securing an initial tranche of roughly 1.6 million shares of its common stock within the initial week. The ultimate number of shares repurchased will be determined based on the volume-weighted average price of Rambus' common stock throughout the transaction period, with a discount applied. This initiative is part of a larger share repurchase program previously sanctioned by Rambus' Board of Directors. The program is anticipated to conclude by the close of the third quarter of 2023, underscoring the company's commitment to enhancing shareholder value and maintaining an advantageous position in the market.

Rambus Inc. provides semiconductor products in the United States, Taiwan, South Korea, Japan, Europe, Canada, Singapore, Asia, and internationally. It offers DDR memory interface chips to module manufacturers and OEMs; physical interface and companion digital controller IPs for SoC designers; and industry-standard interface solutions, such as 28G, 32G, 56G, and 112G SerDes, as well as PCIe 5.0. The company also provides memory interface solutions that include HBM Gen2 and GDDR6; and security IP cores and protocols, as well as a portfolio of patents that covers memory architecture, high-speed serial links, and security products. In addition, it offers technology licenses to support the implementation and adoption of technology in their products or services; and a range of services, which include know-how and technology transfer, product design and development, system integration, and other services. The company markets its products and services through its direct sales force and distributors. Rambus Inc. was founded in 1990 and is headquartered in Sunnyvale, California.


Sector: Financial Services
Industry: Banks—Regional

Princeton Bancorp, Inc. (BPRN) recently unveiled its 2023 stock repurchase program, a testament to the company's confidence in its growth trajectory. As the parent company of The Bank of Princeton, the institution is set to repurchase up to 5% of its outstanding common stock, amounting to approximately 314,000 shares, at a maximum cost of $10.7 million. The company's keen focus on shareholder interests is underscored by its commitment to repurchasing shares only when the per-share price falls below its tangible book value per share. This dynamic program offers flexibility as it may involve open market or privately negotiated transactions, ensuring compliance with regulatory guidelines such as Rule 10b-18 under the Exchange Act. The program's adaptability, considering market conditions, trading prices, and the company's financial performance, highlights its potential to generate value for both the company and its shareholders.

The Bank of Princeton engages in the provision of personal, business lending, and deposit services. The company is headquartered in Princeton, New Jersey and currently employs 179 full-time employees. The Bank provides personal and business lending and deposit services. The company operates through 19 branches across New Jersey, Princeton, Bordentown, Browns Mills, Chesterfield, Cream Ridge, Deptford, Hamilton, Lambertville, Lawrenceville, Monroe, Montgomery, New Brunswick, Pennington, and Sicklerville. The Bank’s loan portfolio consists of variable-rate and fixed-rate loans with a focus on commercial real estate lending. Its loan portfolio consists of commercial real estate and multi-family, commercial and industrial loans, construction loans, residential first-lien mortgage loans, home equity loans and lines of credit and consumer loans. Its deposit services are comprised of a range of deposit products, including checking accounts, savings accounts, attorney trust accounts, money market accounts, and certificates of deposit.


Sector: Financial Services
Industry: Asset Management

GCM Grosvenor (Nasdaq: GCMG), a prominent player in global alternative asset management solutions, has unveiled its Q2 2023 results, showcasing robust performance. Michael Sacks, the company's Chairman and CEO, expressed satisfaction with the quarter's outcome, highlighting a remarkable 50% surge in fundraising compared to Q1, amounting to $1.5 billion. Notably, the company's growth trajectory remains steadfast, prompting an upward revision in its share repurchase program to a substantial $115 million.

Grosvenor Capital Management, L.P. is a privately owned hedge fund sponsor. The firm primarily provides its services to pooled investment vehicles. It also provides its services to investment companies, high net worth individuals, pension and profit sharing plans and state or municipal government entities. The firm invests in equity and alternative investment markets of the United States and internationally. The firm focuses on primary fund investments, secondary fund investments, and co-investments with a focus on buyout, distressed debt, mezzanine, infrastructure, real estate, venture capital/growth equity investments. The firm seeks to make regionally-focused investments in middle-market buyout. The firm employs fundamental and quantitative analysis. Grosvenor Capital Management L.P. was founded in 1971 and is based in Chicago, Illinois with additional offices in North America, Asia and the United Kingdom.


Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic

Collegium Pharmaceutical, Inc. (COLL -1.22%) recently took a strategic step to enhance shareholder value by authorizing a $100 million share repurchase program, reaffirming their confidence in the company's trajectory. The company just announced an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of its common stock. This move follows their commitment to optimizing their capital deployment strategy and underscores the belief in their strong pain portfolio. Joe Ciaffoni, Collegium's President and CEO, emphasized the company's intention to create value for shareholders through focused business development, debt reduction, and opportunistic share repurchases.

Under the terms of the ASR agreement, Collegium will pay $50 million to Jefferies LLC and will receive an initial delivery of approximately 1.7 million shares, based on the closing stock price of $23.49 on August 4, 2023. This initial transaction represents around 80% of the expected total shares to be repurchased. The remaining shares will be determined based on the volume-weighted average prices during the ASR term. The completion of the ASR is projected in the fourth quarter of 2023. Having around 34.7 million shares outstanding as of June 30, 2023, Collegium's move aligns with its commitment to drive value for shareholders while solidifying its strategic growth stance in the pharmaceutical sector.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.


Sector: Financial Services
Industry: Banks—Regional

First Financial Northwest, Inc. (NASDAQ GS: FFNW) recently announced significant developments. The company, which serves as the parent entity for First Financial Northwest Bank, unveiled plans that reflect its commitment to both rewarding shareholders and bolstering its financial position.

One notable step is the declaration of a quarterly cash dividend of $0.13 per share on the company's outstanding common stock. Scheduled for payment on September 22, 2023, this dividend stands as a testament to the company's strong financial health and its dedication to providing value to its shareholders.

Moreover, signaling a keen focus on optimizing its capital structure, First Financial Northwest, Inc.'s Board of Directors authorized a stock buyback program. Under this initiative, the company is empowered to repurchase up to 5% of its outstanding common stock, equating to approximately 457,000 shares. This move aligns with Rule 10b-18 of the Securities Exchange Act of 1934 and demonstrates the company's strategic approach to leverage market conditions and corporate considerations. The stock repurchase program is set to commence around August 10, 2023, and is expected to conclude by March 16, 2024. As market dynamics and corporate strategies evolve, the exact number of shares to be repurchased remains subject to change, underscoring the flexibility inherent in the plan.

First Financial Northwest, Inc. operates as the holding company for First Financial Northwest Bank that provides commercial banking services in Washington. The company offers a range of deposit products, including noninterest bearing accounts, interest-bearing demand accounts, money market deposit accounts, statement savings accounts, and certificates of deposit. Its loan products comprise one-to-four family residential loans; multifamily and commercial real estate loans; construction/land loans for the construction of single-family residences, condominiums, townhouses, multifamily properties, and residential developments; business loans; and consumer loans, such as home equity loans and savings account loans. The company primarily serves the greater Puget Sound region of King, as well as Pierce, Snohomish, and Kitsap counties, Washington through its full-service banking office in Renton, Washington; and eleven additional branches in King and Snohomish counties, Washington. First Financial Northwest, Inc. was founded in 1923 and is headquartered in Renton, Washington.


Sector: Healthcare
Industry: Drug Manufacturers—General

Bristol Myers Squibb (BMY) recently made a noteworthy announcement regarding its decision to engage in accelerated share repurchase (ASR) transactions. The company has proactively entered into agreements with prominent financial institutions, including Bank of America, Citibank, JPMorgan Chase Bank, and Morgan Stanley & Co. LLC, collectively termed as the "ASR Agreements." This strategic move aims to repurchase an aggregate sum of $4 billion worth of Bristol Myers Squibb common stock.

This decision is aligned with the company's ongoing board-authorized, multi-year share repurchase program. After factoring in the ASR transactions, Bristol Myers Squibb is left with an authorization to repurchase approximately $2 billion in shares. Funding for these repurchases will be sourced from the company's existing cash reserves. An estimated 85 percent of the repurchased shares are expected to be in Bristol Myers Squibb's possession by August 10, 2023, with the total number of shares to be acquired being determined based on a discount relative to the volume-weighted average price of their common stock throughout the ASR transactions' terms. The settlement of these ASR transactions is projected to be finalized in the fourth quarter of 2023.

Bristol-Myers Squibb Company is a global biopharmaceutical firm specializing in discovering, developing, manufacturing, and distributing innovative products across hematology, oncology, cardiovascular, and immunology therapeutic areas. Their notable products include Opdivo for anti-cancer applications, Eliquis for stroke prevention and venous thromboembolic disorders, and Orencia for active RA patients. They offer a range of treatments such as Sprycel for leukemia, Yervoy for melanoma, Empliciti for multiple myeloma, and Baraclude for chronic hepatitis B. Collaborating with various partners, including Pfizer, Otsuka, and Astrazeneca, the company has a rich history since its founding in 1887, evolving from Bristol-Myers Company to Bristol-Myers Squibb Company in 1989. It is headquartered in New York, New York.


Sector: Technology
Industry: Semiconductors

Magnachip Semiconductor Corporation (MX) recently unveiled its second-quarter 2023 financial results, reflecting both ongoing macro challenges and promising improvements. Despite facing such challenges, the company's Power business exhibited sequential growth attributed to its Industrial and Automotive applications. Furthermore, Magnachip has been actively engaged in design-in and design-win initiatives, fostering a favorable trajectory. The company's CEO, YJ Kim, expressed optimism about its Display business, highlighted by collaborations with a new global panel customer. This partnership positions Magnachip to capitalize on the expanding Asian OLED market, leveraging the distinct competitive advantages of its products.

Amid its growth prospects, Magnachip displayed its commitment to shareholders by authorizing a stock buyback program amounting to $50 million. This strategic move underscores the company's dedication to enhancing shareholder value. Magnachip's financial snapshot for Q2 2023 revealed intriguing dynamics. While Standard Products Business revenues experienced a decrease, the Power Solutions division reported an uptick, suggesting potential momentum. Gross profit margin also showed improvement, climbing 1.0 percentage point to 22.2%. Adjusted financial metrics highlighted a positive shift in operating income, adjusted EBITDA, and adjusted net income, showcasing the company's efforts to steer its performance in a positive direction.

Looking ahead, Magnachip envisions further growth in its Power business for Q3, anticipating an upward trajectory. The company projects revenues in the range of $59 million to $65 million, with a gross profit margin of 22.5% to 24.5%. These predictions reflect Magnachip's proactive stance in navigating its operational landscape and seizing opportunities for sustained advancement.

MagnaChip Semiconductor Corporation and its subsidiaries specialize in designing, manufacturing, and distributing analog and mixed-signal semiconductor solutions for a wide array of applications, including communication, IoT, consumer electronics, industrial, and automotive sectors. The company operates in two segments: Foundry Services Group, providing foundry services for various semiconductor products, and Standard Products Group, offering display solutions and power management semiconductor products for a range of electronic devices. Serving original equipment manufacturers, design manufacturers, and electronics service providers, MagnaChip operates globally through direct sales and a network of distributors. The company is headquartered in Luxembourg City, Luxembourg.

All data was sourced from LevelFields AI

Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better trader.

Free Trial: Signup for 1 Free Alert Per Week

Add your email to get alerts & the report.

Get 1 free alert per week via email

Upgrade if you want more or platform access

We'll also send you a free report

or Click Here to get full access now

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.